Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA.

AIDS. 2007 Nov 12;21(17):2315-21.

PMID:
18090280
2.

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.

PMID:
17721395
3.

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW.

PLoS Pathog. 2007 Apr;3(4):e46.

4.

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA 3rd, Klingman KL, Gulick RM; ACTG A5166s Protocol Team.

J Infect Dis. 2007 Apr 15;195(8):1169-76. Epub 2007 Mar 6.

PMID:
17357053
5.

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel.

JAMA. 2006 Aug 16;296(7):827-43.

PMID:
16905788
6.

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.

Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J Jr, Quinn TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, Siliciano RF.

J Virol. 2006 Jul;80(13):6441-57.

7.

Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus.

Rouzine IM, Sergeev RA, Glushtsov AI.

Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):666-71. Epub 2006 Jan 5.

8.

Perils at mucosal front lines for HIV and SIV and their hosts.

Haase AT.

Nat Rev Immunol. 2005 Oct;5(10):783-92. Review.

PMID:
16200081
9.

Emerging drug targets for antiretroviral therapy.

Reeves JD, Piefer AJ.

Drugs. 2005;65(13):1747-66. Review.

PMID:
16114975
10.

Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.

Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT.

Nature. 2005 Apr 28;434(7037):1148-52.

PMID:
15793562
11.

Evolution of human immunodeficiency virus under selection and weak recombination.

Rouzine IM, Coffin JM.

Genetics. 2005 May;170(1):7-18. Epub 2005 Mar 2.

12.

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF.

JAMA. 2005 Feb 16;293(7):817-29.

PMID:
15713771
13.

Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells.

Zhou Y, Zhang H, Siliciano JD, Siliciano RF.

J Virol. 2005 Feb;79(4):2199-210.

14.

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.

Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW.

Science. 2004 Jul 23;305(5683):528-32. Epub 2004 Jul 8.

15.

Resistance to apoptosis: mechanism for the development of HIV reservoirs.

Lum JJ, Badley AD.

Curr HIV Res. 2003 Jul;1(3):261-74. Review.

PMID:
15046251
16.
17.

HIV-1 pathogenesis.

Stevenson M.

Nat Med. 2003 Jul;9(7):853-60. Review.

PMID:
12835705
18.

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Strain MC, G√ľnthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4819-24. Epub 2003 Apr 8.

19.

Determining the relative efficacy of highly active antiretroviral therapy.

Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, Ruiz N, Brun S, Sun E, Perelson AS, Ho DD, Markowitz M.

J Infect Dis. 2003 Mar 15;187(6):896-900. Epub 2003 Mar 6.

PMID:
12660935
20.

Mathematical models of HIV pathogenesis and treatment.

Wodarz D, Nowak MA.

Bioessays. 2002 Dec;24(12):1178-87. Review.

PMID:
12447982

Supplemental Content

Support Center